Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Etanercept in Moderate to Severe Psoriasis
NCT00581165Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2006
- Primary completion
- Aug 2007
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, open-label, single-arm trial of etanercept in psoriasis, sponsored by Pfizer. Primary endpoints: Dermatology Quality of Life Index at 18 months, Psoriasis Quality of Life Index at 18 months and 1 more. Started Feb 2006; status: completed.
02
Drugs
etanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00581165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581165.